Company / Free Cash Flow
INOVIO PHARMACEUTICALS, INC. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$104.6M
FY2025
5-year range
-$216.9M / -$98.8M
FY2021-FY2025
Trend
+16.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$217M to -$105M over the past 2 years.
Based on SEC 10-K filings.
-$105M in FY2025.
Improved from -$217M to -$105M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 16.1% year-over-year.
- Peak free cash flow was recorded in FY2017.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$104.6M | +16.1% |
| FY2024 | -$124.7M | +42.5% |
| FY2023 | -$216.9M | -20.9% |
| FY2022 | -$179.5M | -81.6% |
| FY2021 | -$98.8M | -30.7% |
| FY2020 | -$75.6M | -2.9% |
| FY2019 | -$73.5M | -12.6% |
| FY2018 | -$65.3M | -329.0% |
| FY2017 | -$15.2M | +51.2% |
| FY2016 | -$31.2M | -100.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026